Holen Sie sich die Stockscreener-App
3.78
5.00%
0.18
Handel nachbörslich:
3.71
-0.07
-1.85%
Schlusskurs vom Vortag:
$3.60
Offen:
$3.6
24-Stunden-Volumen:
80,687
Relative Volume:
3.01
Marktkapitalisierung:
$176.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.82%
1M Leistung:
-7.80%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.50
$3.8398
1-Wochen-Bereich:
$3.50
$3.99
52-Wochen-Spanne:
$3.50
$4.8816
Capsovision Inc Stock (CV) Company Profile
Firmenname
Capsovision Inc
Sektor
Branche
Telefon
(408) 370-4790
Adresse
18805 COX AVENUE SUITE 250, SARATOGA
Vergleichen Sie CV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
3.78 | 170.73M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
132.81 | 228.80B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.29 | 158.04B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.34 | 149.08B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.85 | 119.71B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
80.96 | 48.01B | 5.69B | 1.41B | 577.90M | 6.95 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Eingeleitet | Roth Capital | Buy |
| 2025-07-28 | Eingeleitet | The Benchmark Company | Speculative Buy |
Capsovision Inc Aktie (CV) Neueste Nachrichten
CapsoVision chief financial officer steps down; company begins search for successor - Investing.com
CapsoVision CFO Kevin Lundquist Resigns - MarketWatch
Capsovision says Kevin Lundquist steps down as CFOSEC filing - MarketScreener
CapsoVision CFO Kevin Lundquist Steps Down - TipRanks
Ingestible Sensors Market Set for Dynamic Growth with Key Players CapsoVision, Inc., BodyCAP, etectRx - openPR.com
Head to Head Comparison: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Smart Pills Market Worth US$1.30 Billion By 2030 With 11.2% CAGR - Barchart.com
Smart Pills Market worth US$1.30 billion by 2030 with 11.2% CAGR - openPR.com
FY2028 EPS Estimates for CapsoVision Lowered by Roth Capital - MarketBeat
Critical Analysis: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Insider Transactions Reported | CapsoVision(CV)saw insider trading activity on 8/22/2025 - AInvest
FY2028 EPS Estimates for CapsoVision Cut by Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Issues Earnings Results - MarketBeat
CapsoVision 2025 Q2 Earnings Net Loss Narrows 12.2% - AInvest
CapsoVision Reports Second Quarter 2025 Financial Results - GlobeNewswire
CapsoVision Reports Revenue Growth and IPO Success - TipRanks
CapsoVision Revenue Jumps 17 Percent - AOL.com
Smart Pills Company Evaluation Report 2025 | Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies - Yahoo Finance
CapsoVision (NASDAQ:CV) versus ReShape Lifesciences (OTCMKTS:RSLSD) Head to Head Comparison - Defense World
Reviewing ReShape Lifesciences (OTCMKTS:RSLSD) and CapsoVision (NASDAQ:CV) - Defense World
CapsoVision, Inc.'s Quiet Period Set To Expire on August 11th (NASDAQ:CV) - MarketBeat
CapsoVision, Inc.’s (NASDAQ:CV) Quiet Period Will End on August 11th - Defense World
Is capsovision scam - AInvest
Roth Capital Predicts CapsoVision's Q2 Earnings (NASDAQ:CV) - MarketBeat
CapsoVision (NASDAQ:CV) Raised to Strong-Buy at Roth Capital - MarketBeat
Understanding the risks associated with CapsoVision's stock - AInvest
CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewswire
Capsovision, Inc. shares fall 2.19% intraday as Kioxia Corporation announces new UFS 4.1 devices for automotive applications. - AInvest
Q2 Earnings Estimate for CapsoVision Issued By Roth Capital - Defense World
Roth Capital Upgrades CapsoVision (NASDAQ:CV) to Strong-Buy - Defense World
CapsoVision (NASDAQ:CV) Rating Increased to Strong-Buy at Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Upgraded at Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Upgraded by Roth Capital to Strong-Buy Rating - Defense World
CapsoVision (NASDAQ:CV) Raised to “Strong-Buy” at Roth Capital - Defense World
Capsovision, Inc. shares rise 3.45% intraday after Canon Inc. announces share buyback plan. - AInvest
CapsoVision is a buy, this analyst says - Cantech Letter
Capsovision, Inc. shares fall 1.15% premarket after Canon Inc. announced a buyback plan. - AInvest
CapsoVision (NASDAQ:CV) Earns Speculative Buy Rating from Analysts at Benchmark - MarketBeat
Benchmark Co. Initiates CapsoVision(CV.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
CapsoVision: Benchmark initiates coverage with Speculative Buy rating, $5 price target. - AInvest
CapsoVision stock initiated with Speculative Buy rating at Benchmark By Investing.com - Investing.com Australia
Benchmark starts CapsoVision with a Speculative Buy as CapsoCam Plus takes share - TipRanks
CapsoVision initiated with a Buy at Roth Capital - TipRanks
CapsoVision stock initiated with Buy rating at Roth/MKM on GI imaging potential - Investing.com Nigeria
CapsoVision stock initiated with Speculative Buy rating at Benchmark - Investing.com
CapsoVision Completes $27.5 Million Nasdaq IPO - Global Legal Chronicle
CapsoVision enters development agreement with Canon and announces partial IPO overallotment exercise - Investing.com India
Finanzdaten der Capsovision Inc-Aktie (CV)
Es liegen keine Finanzdaten für Capsovision Inc (CV) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):